Efforts to identify circulating factors that predict severity of acute lung injury/acute respiratory distress syndrome(ALI/ARDS)patients is unrevealing. The primary purpose of this study is to verify circRNAs and microRNAs might be potential novel ALI/ARDS biomarkers and could play roles in pathogenesis of ALI/ARDS.
Acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) is a devastating cause of morbidity and mortality characterized by alveolar epithelial and endothelial injury. Despite recent advances in pathogenetic mechanisms and therapy strategies of ALI, efforts to identify circulating factors that predict severity of ALI/ARDS patients have been unrevealing. Circular RNAs (circRNAs) are a novel class of endogenous non-coding RNA with a covalently continuous closed-loop structure. Compared with traditional linear RNAs, circRNAs are more stable and resistant to RNase R due to the absence of 5' caps and 3' tails, which show clear advantages in acting as novel molecular biomarkers for many diseases. In addition, many studies have reported that circRNAs can bind to microRNAs (miRNAs), acting as "miRNA sponges" which are named competitive endogenous RNAs (ceRNAs), and can regulate gene expression at the transcriptional or post-transcriptional level. Evidence indicates that circRNAs play important roles in cancers and other diseases such as tuberculosis and intervertebral disc degeneration. As no published research has studied the expression and role of circRNAs in the pathology and pathogenesis of ALI/ARDS, the investigators aimed to validate the aberrant expression of circRNAs in ALI/ARDS and explore the potential pathological mechanism in which circRNAs are involved.
Study Type
OBSERVATIONAL
Enrollment
250
Department of Burn and Trauma Sugery, Changhai Hospital
Shanghai, Shanghai Municipality, China
RECRUITINGNumber of Participants Receiving Mechanical Ventilation
Time frame: up to 28 days
Fraction of Inspired Oxygen (FiO2)/Partial Arterial Oxygen Pressure (PO2)
Time frame: up to 28 days
Acute Physiology and Chronic Health Evaluation (APACHE) II Scores
APACHE II scores range from 0 to 71. A higher values represent a worse outcome
Time frame: up to 28 days
plasma circRNAs
Time frame: Day 3
plasma microRNAs
Time frame: Day 3
Length of Stay in the ICU
Time frame: 1 year
Length of Hospital Stay
Time frame: 1 year
Days of Unassisted Ventilation
Time frame: 1 year
Death
Time frame: up to 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.